天然多糖聚合物的创新应用在膀疾病的静脉内疗法中
Ke Hu1, Miaomiao Xiao2, Siwen Chen2
1Research Center for Biomedical Materials, Shenyang Key Laboratory of Biomedical Polymers, Engineering Research Center of Ministry of Education for Minimally Invasive Gastrointestinal Endoscopic Techniques, Shengjing Hospital of China Medical University, Shenyang 11004, China; Department of Urology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Carbohydrate polymers
|February 20, 2025
概括
天然多糖类,如氨酸和奇托,显示出治疗膀疾病的潜力. 这些材料通过调节膀壁的透性来改善药物输送,提高治疗效率和患者的坚持.
科学领域:
- 生物材料科学 生物材料科学
- 药物运输 药物运输 药物运输
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 膀疾病,如癌症和间歇性囊炎,由于膀壁的透性发生变化,对药物的有效性构成挑战.
- 传统的肠道疗法面临着快速药物清除和膀的自然屏障功能等问题.
- 自然的多糖提供独特的特性,可以克服药物输送中的这些局限性.
研究的目的:
- 审查自然多糖合物聚合物调节膀壁透性的机制.
- 突出基于多糖的肠道药物输送系统 (IDDS) 的进展.
- 探索这些材料在创新性膀疾病治疗中的潜力.
主要方法:
- 关于基于多糖的静脉内药物输送的科学文献的综述.
- 在调节膀透性方面,分析涉及酸 (HA) 和酸 (CS) 的机制.
- 配送平台的分类,包括纳米粒子,水凝和复合材料.
主要成果:
- 像HA和CS这样的多糖类可以修复紧张的结节,减少炎症,提高膀壁的透性.
- 不同的输送平台 (纳米粒子,水凝等) 利用这些特性改善药物保留和生物可用性.
- 这些材料显示了持续药物释放和膀内的向输送的潜力.
结论:
- 天然多糖体聚合物由于其生物相容性和修改膀通透性的能力,对静脉内疗法具有前景.
- 基于多糖的IDDS为膀疾病提供了增强的药物保留,生物可用性和患者的坚持.
- 这些进展为开发用于膀疾病的新型和有效治疗提供了坚实的基础.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
125
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
125
01:17Drugs for Treatment of Diarrhea-Predominant IBS
140
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
140